Lexaria Bioscience - Warrants (11/01/2026) Current Cash

The latest current cash for LEXXW is $3.5M as of May 2026. That compares with $4.6M in the prior-year period — down 24.3% year over year. Investors often review this figure alongside Lexaria Bioscience - Warrants (11/01/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LEXXW's current cash moved from $4.6M to $3.5M — a 24.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lexaria Bioscience - Warrants (11/01/2026)'s operating scale or balance-sheet position.

A current cash figure of $3.5M for LEXXW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LEXXW's current cash ($3.5M), review year-over-year change from $4.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lexaria Bioscience - Warrants (11/01/2026)'s current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.